Cargando…

Measles Vaccination Supports Millennium Development Goal 4: Increasing Coverage and Increasing Child Survival in Northern Ghana, 1996–2012

BACKGROUND: Measles vaccine (MV) administered as the last vaccine after the third dose of diphtheria-tetanus-pertussis (DTP) may be associated with better child survival unrelated to prevention of measles infection. Other studies have shown that MV administered after DTP was more beneficial and was...

Descripción completa

Detalles Bibliográficos
Autores principales: Welaga, Paul, Hodgson, Abraham, Debpuur, Cornelius, Aaby, Peter, Binka, Fred, Azongo, Daniel, Oduro, Abraham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816587/
https://www.ncbi.nlm.nih.gov/pubmed/29487845
http://dx.doi.org/10.3389/fpubh.2018.00028
_version_ 1783300710051348480
author Welaga, Paul
Hodgson, Abraham
Debpuur, Cornelius
Aaby, Peter
Binka, Fred
Azongo, Daniel
Oduro, Abraham
author_facet Welaga, Paul
Hodgson, Abraham
Debpuur, Cornelius
Aaby, Peter
Binka, Fred
Azongo, Daniel
Oduro, Abraham
author_sort Welaga, Paul
collection PubMed
description BACKGROUND: Measles vaccine (MV) administered as the last vaccine after the third dose of diphtheria-tetanus-pertussis (DTP) may be associated with better child survival unrelated to prevention of measles infection. Other studies have shown that MV administered after DTP was more beneficial and was associated with lower mortality compared with DTP administered after MV or DTP administered simultaneously with MV. We compared the difference in mortality between measles vaccinated after DTP3 and measles-unvaccinated children in Navrongo, Ghana. METHODS: This was a follow-up study involving annual cohort of children aged 9–23 months from 1996 to 2012. We assessed survival in relation to the measles vaccination status within the first 12 months from interview date and until 5 years of age using Cox proportional hazards models. RESULTS: In all, 38,333 children were included in the study. The proportion of children vaccinated with MV-after-DTP3 increased from 45% in 1996 to 95% in 2012. The adjusted hazard ratio (HR) for measles unvaccinated compared with MV-after-DTP3 vaccinated children was 1.38 (1.15–1.66) in the first 12 months after assessment of vaccination status and 1.22 (1.05–1.41) with follow-up to 5 years of age. The national immunization days campaigns with oral polio vaccine or MV might have reduced the effect of being MV-after-DTP3 vaccinated vs MV-unvaccinated. For 12 months of follow-up, the HR before a campaign for MV-unvaccinated children was 1.63 (1.23–2.17) compared to those who received MV-after-DTP3. After the campaign, the HR reduced to 1.23 (0.97–1.54). Stratifying the analysis by sex, measles-unvaccinated boys had a HR of 1.69 (1.33–2.61) compared to measles-unvaccinated girls who had a HR 1.06 (0.79–1.40) during 1-year follow-up. In 1989, only 7% of children in the area had received MV-after-DTP3; the increase in MV-after-DTP3 coverage from 1989 to 2012 may have lowered mortality rate among children aged 9 months to 3 years by 24%. CONCLUSION: Though an observational study, our findings suggest that measles vaccination, administered in the recommended sequence, is associated with improved child survival and may have contributed importantly to the mortality decline toward the achievement of Millennium Development Goal 4.
format Online
Article
Text
id pubmed-5816587
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58165872018-02-27 Measles Vaccination Supports Millennium Development Goal 4: Increasing Coverage and Increasing Child Survival in Northern Ghana, 1996–2012 Welaga, Paul Hodgson, Abraham Debpuur, Cornelius Aaby, Peter Binka, Fred Azongo, Daniel Oduro, Abraham Front Public Health Public Health BACKGROUND: Measles vaccine (MV) administered as the last vaccine after the third dose of diphtheria-tetanus-pertussis (DTP) may be associated with better child survival unrelated to prevention of measles infection. Other studies have shown that MV administered after DTP was more beneficial and was associated with lower mortality compared with DTP administered after MV or DTP administered simultaneously with MV. We compared the difference in mortality between measles vaccinated after DTP3 and measles-unvaccinated children in Navrongo, Ghana. METHODS: This was a follow-up study involving annual cohort of children aged 9–23 months from 1996 to 2012. We assessed survival in relation to the measles vaccination status within the first 12 months from interview date and until 5 years of age using Cox proportional hazards models. RESULTS: In all, 38,333 children were included in the study. The proportion of children vaccinated with MV-after-DTP3 increased from 45% in 1996 to 95% in 2012. The adjusted hazard ratio (HR) for measles unvaccinated compared with MV-after-DTP3 vaccinated children was 1.38 (1.15–1.66) in the first 12 months after assessment of vaccination status and 1.22 (1.05–1.41) with follow-up to 5 years of age. The national immunization days campaigns with oral polio vaccine or MV might have reduced the effect of being MV-after-DTP3 vaccinated vs MV-unvaccinated. For 12 months of follow-up, the HR before a campaign for MV-unvaccinated children was 1.63 (1.23–2.17) compared to those who received MV-after-DTP3. After the campaign, the HR reduced to 1.23 (0.97–1.54). Stratifying the analysis by sex, measles-unvaccinated boys had a HR of 1.69 (1.33–2.61) compared to measles-unvaccinated girls who had a HR 1.06 (0.79–1.40) during 1-year follow-up. In 1989, only 7% of children in the area had received MV-after-DTP3; the increase in MV-after-DTP3 coverage from 1989 to 2012 may have lowered mortality rate among children aged 9 months to 3 years by 24%. CONCLUSION: Though an observational study, our findings suggest that measles vaccination, administered in the recommended sequence, is associated with improved child survival and may have contributed importantly to the mortality decline toward the achievement of Millennium Development Goal 4. Frontiers Media S.A. 2018-02-12 /pmc/articles/PMC5816587/ /pubmed/29487845 http://dx.doi.org/10.3389/fpubh.2018.00028 Text en Copyright © 2018 Welaga, Hodgson, Debpuur, Aaby, Binka, Azongo and Oduro. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Welaga, Paul
Hodgson, Abraham
Debpuur, Cornelius
Aaby, Peter
Binka, Fred
Azongo, Daniel
Oduro, Abraham
Measles Vaccination Supports Millennium Development Goal 4: Increasing Coverage and Increasing Child Survival in Northern Ghana, 1996–2012
title Measles Vaccination Supports Millennium Development Goal 4: Increasing Coverage and Increasing Child Survival in Northern Ghana, 1996–2012
title_full Measles Vaccination Supports Millennium Development Goal 4: Increasing Coverage and Increasing Child Survival in Northern Ghana, 1996–2012
title_fullStr Measles Vaccination Supports Millennium Development Goal 4: Increasing Coverage and Increasing Child Survival in Northern Ghana, 1996–2012
title_full_unstemmed Measles Vaccination Supports Millennium Development Goal 4: Increasing Coverage and Increasing Child Survival in Northern Ghana, 1996–2012
title_short Measles Vaccination Supports Millennium Development Goal 4: Increasing Coverage and Increasing Child Survival in Northern Ghana, 1996–2012
title_sort measles vaccination supports millennium development goal 4: increasing coverage and increasing child survival in northern ghana, 1996–2012
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816587/
https://www.ncbi.nlm.nih.gov/pubmed/29487845
http://dx.doi.org/10.3389/fpubh.2018.00028
work_keys_str_mv AT welagapaul measlesvaccinationsupportsmillenniumdevelopmentgoal4increasingcoverageandincreasingchildsurvivalinnorthernghana19962012
AT hodgsonabraham measlesvaccinationsupportsmillenniumdevelopmentgoal4increasingcoverageandincreasingchildsurvivalinnorthernghana19962012
AT debpuurcornelius measlesvaccinationsupportsmillenniumdevelopmentgoal4increasingcoverageandincreasingchildsurvivalinnorthernghana19962012
AT aabypeter measlesvaccinationsupportsmillenniumdevelopmentgoal4increasingcoverageandincreasingchildsurvivalinnorthernghana19962012
AT binkafred measlesvaccinationsupportsmillenniumdevelopmentgoal4increasingcoverageandincreasingchildsurvivalinnorthernghana19962012
AT azongodaniel measlesvaccinationsupportsmillenniumdevelopmentgoal4increasingcoverageandincreasingchildsurvivalinnorthernghana19962012
AT oduroabraham measlesvaccinationsupportsmillenniumdevelopmentgoal4increasingcoverageandincreasingchildsurvivalinnorthernghana19962012